ATE483711T1 - Spiroindolinonderivate - Google Patents

Spiroindolinonderivate

Info

Publication number
ATE483711T1
ATE483711T1 AT07712430T AT07712430T ATE483711T1 AT E483711 T1 ATE483711 T1 AT E483711T1 AT 07712430 T AT07712430 T AT 07712430T AT 07712430 T AT07712430 T AT 07712430T AT E483711 T1 ATE483711 T1 AT E483711T1
Authority
AT
Austria
Prior art keywords
spiroindolinone derivatives
spiroindolinone
derivatives
Prior art date
Application number
AT07712430T
Other languages
English (en)
Inventor
Li Chen
Qingjie Ding
Jin-Jun Liu
Song Yang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE483711T1 publication Critical patent/ATE483711T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07712430T 2006-03-13 2007-03-05 Spiroindolinonderivate ATE483711T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78195806P 2006-03-13 2006-03-13
US88175607P 2007-01-22 2007-01-22
PCT/EP2007/052038 WO2007104664A1 (en) 2006-03-13 2007-03-05 Spiroindolinone derivatives

Publications (1)

Publication Number Publication Date
ATE483711T1 true ATE483711T1 (de) 2010-10-15

Family

ID=38179455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07712430T ATE483711T1 (de) 2006-03-13 2007-03-05 Spiroindolinonderivate

Country Status (15)

Country Link
US (1) US20070213341A1 (de)
EP (1) EP1996590B1 (de)
JP (1) JP5038337B2 (de)
KR (1) KR101131031B1 (de)
AR (1) AR059957A1 (de)
AT (1) ATE483711T1 (de)
AU (1) AU2007224505B2 (de)
BR (1) BRPI0709605A2 (de)
CA (1) CA2645062A1 (de)
DE (1) DE602007009650D1 (de)
IL (1) IL193641A0 (de)
NO (1) NO20083726L (de)
RU (1) RU2435771C2 (de)
TW (1) TW200801000A (de)
WO (1) WO2007104664A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
US7553833B2 (en) * 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US8134001B2 (en) * 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) * 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) * 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
EP2108641A1 (de) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Neue substituierte Spiro[Cycloalkyl-1,3'-indo]-2'(1'H)-on-Derivate und ihre Verwendung als p38 mitogen-activated Kinase Inhibitoren
EP2113503A1 (de) * 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. Neue substituierte Indolin-2-on- Derivate und ihre Verwendung als p39 mitogen-activated Kinase Inhibitoren
KR100915320B1 (ko) 2008-09-29 2009-09-03 (주)메디룬 생리통완화를 위한 휴대용 조합자극기
US20100190814A1 (en) * 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) * 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
BR112012002214B1 (pt) 2009-07-31 2022-01-25 Global Alliance For Tb Drug Development Análogos de nitroimidazooxazina e nitroimidazooxazol, seus usos e composição farmacêutica
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9962459B2 (en) * 2010-07-02 2018-05-08 Basf Se Ultrathin fluid-absorbent cores
SG193002A1 (en) 2011-03-10 2013-09-30 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivative
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
CN105358530A (zh) 2013-06-10 2016-02-24 美国安进公司 制备mdm2抑制剂的方法及其结晶形式
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
RS59111B1 (sr) 2014-08-21 2019-09-30 Boehringer Ingelheim Int Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
KR20240158360A (ko) 2015-10-09 2024-11-04 베링거 인겔하임 인터내셔날 게엠베하 Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3527226A4 (de) 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited Kombinationstherapieverfahren mit mdm2-inhibitor und dna-methyltransferase-inhibitor
EP3511334A1 (de) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indol-3,1'-pyrrolo[3,4-c]pyrrol] -2,3'-dion-verbindungen als therapeutische mittel, die tp53 aktivieren
US12296129B2 (en) 2018-03-07 2025-05-13 Soovu Labs, Inc. Systems and methods for improved pain relief from stimulation of thermal fibers
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
HUP0203548A3 (en) * 1999-07-21 2003-04-28 Astrazeneca Ab New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
JP2009530236A (ja) * 2006-03-13 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー スピロインドリノン誘導体

Also Published As

Publication number Publication date
RU2435771C2 (ru) 2011-12-10
TW200801000A (en) 2008-01-01
WO2007104664A1 (en) 2007-09-20
IL193641A0 (en) 2009-05-04
AU2007224505A1 (en) 2007-09-20
KR20080095279A (ko) 2008-10-28
EP1996590B1 (de) 2010-10-06
RU2008140386A (ru) 2010-04-20
KR101131031B1 (ko) 2012-04-12
EP1996590A1 (de) 2008-12-03
AU2007224505B2 (en) 2012-05-03
US20070213341A1 (en) 2007-09-13
JP5038337B2 (ja) 2012-10-03
JP2009529566A (ja) 2009-08-20
AR059957A1 (es) 2008-05-14
CA2645062A1 (en) 2007-09-20
DE602007009650D1 (de) 2010-11-18
BRPI0709605A2 (pt) 2011-07-19
NO20083726L (no) 2008-11-25

Similar Documents

Publication Publication Date Title
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
DE602006019782D1 (de) Kapselperforationsmodul
AT504580A3 (de) Scan-einrichtung
BRPI0813836A2 (pt) Derivados pirazólicos
DE602007000258D1 (de) Kassetteneinspannmechanismus
ATE518837T1 (de) Indazolamidderivate
EP2072519A4 (de) Diarylketiminderivat
DE602006020192D1 (de) Riemenscheibenanorndung
DE502007001629D1 (de) Rfahren
ATE546437T1 (de) Aminomethyl-4-imidazole
DK2152370T3 (da) Aryletherpyridazinonderivater
DE502007000218D1 (de) nsetzungen
DE602007001098D1 (de) Spindelmäheinheit
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007000501D1 (de) Breitbandrichtkoppler
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
DE502007000361D1 (de) Stanznieteinheit
ATE519760T1 (de) Isoxazolimidazolderivate
DE602007000333D1 (de) Napfbefestigungsvorrichtung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1996590

Country of ref document: EP